IntelGenx Technologies Corp. has made changes to its management team. Following the planned retirement of its founder and CEO, Horst Zerbe, the new executive leadership team iwill support continued global growth as a CDMO for oral films and transdermal products, and to prepare for the potential commercialization of RIZAFILM VersaFilm, an oral thin film formulation of rizatriptan benzoate (active ingredient in Merck & Co.’s Maxalt), and Buprenorphine Buccal Film, a generic version of Be...